tiprankstipranks
Inventiva (IVA)
NASDAQ:IVA
US Market
IVA
Inventiva
RESEARCH TOOLSreports

Inventiva (IVA) Stock Forecast & Price Target

624 Followers
See the Price Targets and Ratings of:

IVA Analyst Ratings

Strong Buy
10Ratings
Strong Buy
10 Buy
0 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Inventiva
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IVA Stock 12 Month Forecast

Average Price Target

$15.11
▲(176.23% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Inventiva in the last 3 months. The average price target is $15.11 with a high forecast of $24.00 and a low forecast of $10.00. The average price target represents a 176.23% change from the last price of $5.47.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","7":"$7","13":"$13","19":"$19","25":"$25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$10.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,7,13,19,25],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,6.858461538461539,8.286923076923078,9.715384615384615,11.143846153846154,12.572307692307692,14.00076923076923,15.429230769230768,16.857692307692307,18.286153846153844,19.714615384615385,21.143076923076922,22.57153846153846,{"y":24,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,6.174615384615384,6.919230769230769,7.663846153846153,8.408461538461538,9.153076923076922,9.897692307692306,10.642307692307693,11.386923076923075,12.131538461538462,12.876153846153844,13.62076923076923,14.365384615384615,{"y":15.11,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,5.43,5.781538461538461,6.133076923076922,6.484615384615385,6.836153846153846,7.187692307692307,7.53923076923077,7.890769230769231,8.242307692307692,8.593846153846155,8.945384615384615,9.296923076923077,9.64846153846154,{"y":10,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.14,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":2.425,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.17,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.39,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.26,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.91,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 69, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.3,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 53, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.65,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 65, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1772323200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1775001600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$24.00Average Price Target$15.11Lowest Price Target$10.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on IVA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$20
Buy
265.63%
Upside
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inventiva (NASDAQ: IVA), Tilray (NASDAQ: TLRY) and Apellis Pharmaceuticals (NASDAQ: APLS)
Barclays Analyst forecast on IVA
Eliana Merle
Barclays
Barclays
$18
Buy
229.07%
Upside
Reiterated
04/02/26
Barclays Sticks to Its Buy Rating for Inventiva (IVA)
Guggenheim Analyst forecast on IVA
Seamus Fernandez
Guggenheim
Guggenheim
$11
Buy
101.10%
Upside
Reiterated
04/01/26
Guggenheim Keeps Their Buy Rating on Inventiva (IVA)
Truist Financial Analyst forecast on IVA
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/01/26
Analysts Conflicted on These Healthcare Names: Centessa Pharmaceuticals (NASDAQ: CNTA), Cabaletta Bio (NASDAQ: CABA) and Inventiva (NASDAQ: IVA)
UBS Analyst forecast on IVA
Michael Yee
UBS
UBS
$12
Buy
119.38%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on IVA
Ritu Baral
TD Cowen
TD Cowen
$10
Buy
82.82%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and Palvella Therapeutics (NASDAQ: PVLA)
LifeSci Capital Analyst forecast on IVA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$14
Buy
155.94%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Gain Therapeutics (NASDAQ: GANX)
Stifel Nicolaus Analyst forecast on IVA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$17→$15
Buy
174.22%
Upside
Reiterated
03/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on IVA
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$24
Buy
338.76%
Upside
Reiterated
01/28/26
Analysts' Top Healthcare Picks: Aclaris Therapeutics (ACRS), Inventiva (IVA)
Leerink Partners Analyst forecast on IVA
Thomas Smith
Leerink Partners
Leerink Partners
$12
Buy
119.38%
Upside
Initiated
01/11/26
Inventiva initiated with an Outperform at LeerinkInventiva initiated with an Outperform at Leerink
Piper Sandler Analyst forecast on IVA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$26
Buy
375.32%
Upside
Reiterated
11/25/25
Piper Sandler Keeps Their Buy Rating on Inventiva (IVA)
Wolfe Research Analyst forecast on IVA
Andy Chen
Wolfe Research
Wolfe Research
$13
Buy
137.66%
Upside
Initiated
11/05/25
Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Canaccord Genuity Analyst forecast on IVA
Edward Nash
Canaccord Genuity
Canaccord Genuity
$20
Buy
265.63%
Upside
Reiterated
04/02/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Inventiva (NASDAQ: IVA), Tilray (NASDAQ: TLRY) and Apellis Pharmaceuticals (NASDAQ: APLS)
Barclays Analyst forecast on IVA
Eliana Merle
Barclays
Barclays
$18
Buy
229.07%
Upside
Reiterated
04/02/26
Barclays Sticks to Its Buy Rating for Inventiva (IVA)
Guggenheim Analyst forecast on IVA
Seamus Fernandez
Guggenheim
Guggenheim
$11
Buy
101.10%
Upside
Reiterated
04/01/26
Guggenheim Keeps Their Buy Rating on Inventiva (IVA)
Truist Financial Analyst forecast on IVA
Srikripa Devarakonda
Truist Financial
Truist Financial
―
Buy
―
Reiterated
04/01/26
Analysts Conflicted on These Healthcare Names: Centessa Pharmaceuticals (NASDAQ: CNTA), Cabaletta Bio (NASDAQ: CABA) and Inventiva (NASDAQ: IVA)
UBS Analyst forecast on IVA
Michael Yee
UBS
UBS
$12
Buy
119.38%
Upside
Reiterated
04/01/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Oric Pharmaceuticals (NASDAQ: ORIC) and Biogen (NASDAQ: BIIB)
TD Cowen Analyst forecast on IVA
Ritu Baral
TD Cowen
TD Cowen
$10
Buy
82.82%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), MAIA Biotechnology, Inc. (NYSE MKT: MAIA) and Palvella Therapeutics (NASDAQ: PVLA)
LifeSci Capital Analyst forecast on IVA
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$14
Buy
155.94%
Upside
Reiterated
03/31/26
Analysts Offer Insights on Healthcare Companies: Inventiva (NASDAQ: IVA), Neumora Therapeutics, Inc. (NASDAQ: NMRA) and Gain Therapeutics (NASDAQ: GANX)
Stifel Nicolaus Analyst forecast on IVA
Annabel Samimy
Stifel Nicolaus
Stifel Nicolaus
$17→$15
Buy
174.22%
Upside
Reiterated
03/31/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on IVA
Ananda Ghosh
H.C. Wainwright
H.C. Wainwright
$24
Buy
338.76%
Upside
Reiterated
01/28/26
Analysts' Top Healthcare Picks: Aclaris Therapeutics (ACRS), Inventiva (IVA)
Leerink Partners Analyst forecast on IVA
Thomas Smith
Leerink Partners
Leerink Partners
$12
Buy
119.38%
Upside
Initiated
01/11/26
Inventiva initiated with an Outperform at LeerinkInventiva initiated with an Outperform at Leerink
Piper Sandler Analyst forecast on IVA
Yasmeen Rahimi
Piper Sandler
Piper Sandler
$26
Buy
375.32%
Upside
Reiterated
11/25/25
Piper Sandler Keeps Their Buy Rating on Inventiva (IVA)
Wolfe Research Analyst forecast on IVA
Andy Chen
Wolfe Research
Wolfe Research
$13
Buy
137.66%
Upside
Initiated
11/05/25
Inventiva initiated with an Outperform at Wolfe ResearchInventiva initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Inventiva

3 Months
xxx
Success Rate
3/4 ratings generated profit
75%
Average Return
+24.38%
reiterated a xxx
 rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 75.00% of your transactions generating a profit, with an average return of +24.38% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
4/4 ratings generated profit
100%
Average Return
+96.35%
reiterated a buy rating 7 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +96.35% per trade.
2 Years
xxx
Success Rate
4/4 ratings generated profit
100%
Average Return
+89.68%
reiterated a xxx
 rating 7 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +89.68% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IVA Analyst Recommendation Trends

Rating
Oct 25
Nov 25
Jan 26
Mar 26
Apr 26
Strong Buy
15
16
14
11
12
Buy
1
1
0
0
1
Hold
69
53
65
26
21
Sell
2
3
14
12
11
Strong Sell
0
0
0
0
0
total
87
73
93
49
45
In the current month, IVA has received 13 Buy Ratings, 21 Hold Ratings, and 11 Sell Ratings. IVA average Analyst price target in the past 3 months is 15.11.
Each month's total comprises the sum of three months' worth of ratings.

IVA Financial Forecast

IVA Earnings Forecast

Next quarter’s earnings estimate for IVA is -$0.42 with a range of -$0.54 to -$0.32. The previous quarter’s EPS was -$1.07. IVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.
Next quarter’s earnings estimate for IVA is -$0.42 with a range of -$0.54 to -$0.32. The previous quarter’s EPS was -$1.07. IVA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.

IVA Sales Forecast

Next quarter’s sales forecast for IVA is $576.00K with a range of $0.00 to $2.30M. The previous quarter’s sales results were $33.82K. IVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.
Next quarter’s sales forecast for IVA is $576.00K with a range of $0.00 to $2.30M. The previous quarter’s sales results were $33.82K. IVA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year IVA has Performed in-line its overall industry.

IVA Stock Forecast FAQ

What is IVA’s average 12-month price target, according to analysts?
Based on analyst ratings, Inventiva’s 12-month average price target is 15.11.
    What is IVA’s upside potential, based on the analysts’ average price target?
    Inventiva has 176.23% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IVA a Buy, Sell or Hold?
          Inventiva has a consensus rating of Strong Buy which is based on 10 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Inventiva’s price target?
            The average price target for Inventiva is 15.11. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $24.00 ,the lowest forecast is $10.00. The average price target represents 176.23% Increase from the current price of $5.47.
              What do analysts say about Inventiva?
              Inventiva’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of IVA?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.